Surface-coated polycaprolactone nanoparticles with pharmaceutical application: Structural and molecular mobility evaluation by TD-NMR
Source abstract
Abstract
Abstract The development of nanosystems in the pharmaceutical field has been growing in recent years. Polymers in particular are attractive since they can enable controlled release. Furthermore, surface modification is essential to increase nanosystem stability and prolong the blood circulation time. In this context, the present study obtained polycaprolactone (PCL) nanoparticles coated with poly(ethylene oxide)–poly(propylene oxide) triblock copolymer using the nanoprecipitation method, aiming to evaluate the effect of PCL concentration in this type of pharmaceutical formulation on prolongation of drug release. Nanosuspensions were evaluated by the following techniques: FT-IR, DLS, FESEM, TEM, ZP, TGA, DSC, XRD and TD-NMR. With higher PCL concentration, the particle size also increased and negative surface charge was observed. The nanoparticles' spherical shape was confirmed by FESEM and TEM while XRD and TD-NMR revealed changes in Pluronic chains' organization around the PCL matrix. Although this kind of polymer combination is already known in the pharmaceutical field, structural and molecular mobility evaluation with new perspectives were performed, mainly by XRD and TD-NMR.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Hydrogels: synthesis, properties, applications · Polymer Nanocomposites and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Polymer microspheres for controlled drug release10.1016/j.ijpharm.2004.04.013 ↗
2. A review on: sustained release technology
3. Polymeric nanoparticles assembled with microfluidics for drug delivery across the blood-brain barrier10.1140/epjst/e2015-50266-2 ↗
4. Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the “ouzo region” upon drug loading10.1016/j.ejps.2010.06.007 ↗
5. Emerging frontiers in drug delivery10.1021/jacs.5b09974 ↗
6. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier10.1021/cr200472g ↗
7. Nanoprecipitation and the “Ouzo effect”: application to drug delivery devices10.1016/j.addr.2013.12.009 ↗
8. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
9. Stability of nanosuspensions in drug delivery10.1016/j.jconrel.2013.08.006 ↗
10. Biodegradable polymeric nanoparticles based drug delivery systems10.1016/j.colsurfb.2009.09.001 ↗
11. Polycaprolactone-based biomaterials for tissue engineering and drug delivery: current scenario and challenges10.1080/00914037.2015.1103241 ↗
12. Poloxamers for surface modification of hydrophobic drug carriers and their effects on drug delivery10.1080/15583724.2013.862544 ↗
13. Nanocapsule formation by interfacial polymer deposition following solvent displacement10.1016/0378-5173(89)90281-0 ↗
14. Polymer-based nanocapsules for drug delivery10.1016/j.ijpharm.2009.10.018 ↗
15. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery10.1016/j.jconrel.2016.01.034 ↗
16. Controlling drug nanoparticle formation by rapid precipitation10.1016/j.addr.2011.04.005 ↗
17. Physical and chemical stability of drug nanoparticles10.1016/j.addr.2011.02.001 ↗
18. Freeze-drying of nanoparticles: formulation, process and storage considerations10.1016/j.addr.2006.09.017 ↗
19. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA–PCL–pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy10.1021/bm5001263 ↗
20. Primary and secondary crystallization processes of poly (e -caprolactone )/styrene oligomer blends investigated by pulsed NMR10.1016/S0032-3861(00)00134-8 ↗
21. Time domain NMR evaluation of poly(vinyl alcohol) xerogels10.1590/0104-1428.2093 ↗
22. Critical effect of segmental dynamics in polybutadiene/clay nanocomposites characterized by solid state 1H NMR spectroscopy10.1021/jp5013472 ↗
23. Conventional and fast field cycling relaxometry study of the molecular dynamics in polymer nanocomposites for use as drug delivery systems10.1166/jnn.2016.12476 ↗
24. Stability of cyclosporine-loaded poly-epsilon-caprolactone nanoparticles10.3109/02652049709006828 ↗
25. Formation of poly (ethylene glycol)-poly(ε-caprolactone) nanoparticles via nanoprecipitation10.1007/BF03218657 ↗
26. Nanoprecipitation and spectroscopic Characterization of curcumin-encapsulated polyester nanoparticles10.1021/acs.langmuir.5b02773 ↗
27. Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy
28. Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics10.1007/s12645-013-0037-4 ↗
29. Development of stevioside pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine10.1016/j.colsurfb.2012.07.005 ↗
30. Synthesis of surfactant free PCL-PEG brushed nanoparticles with tunable degradation kinetics10.1016/j.ijpharm.2013.06.020 ↗
31. Preparation and characterization of polyhydroxybutyrate/polycaprolactone nanocomposites10.1155/2014/572726 ↗
32. A novel melt-dispersion technique for simplistic preparation of chlorpromazine-loaded polycaprolactone nanocapsules10.3390/polym7061145 ↗
33. Preparation and in vitro evaluation of solid dispersions of total flavones of Hippophae rhamnoides L.10.1208/s12249-009-9246-x ↗
34. Crystal structure of f moly-e-caprolactone10.1107/S0567740870005198 ↗
35. Crystal structure of an anhydrous form of trehalose: structure of water channels of trehalose polymorphism10.1021/jp800936z ↗